Contact
searchSearch
HMP Global

News

A nurse and a doctor review information on a computer in a lab clinical study research trial
News
Fenebrutinib for Multiple Sclerosis Returns Significant Phase III Results
03/04/2026
Brionna Mendoza
The pivotal Phase III FENhance 1 trial of fenebrutinib met its primary endpoint in relapsing multiple sclerosis (RMS), demonstrating statistically significant and clinically meaningful reductions in relapse activity.
The pivotal Phase III FENhance 1 trial of fenebrutinib met its primary endpoint in relapsing multiple sclerosis (RMS), demonstrating statistically significant and clinically meaningful reductions in relapse activity.
The pivotal Phase III FENhance 1...
03/04/2026
Neurology
a bowl of fruits and vegetables indicates brain health
News
DASH Diet Linked to Lower Subjective Cognitive Decline Risk
03/02/2026
Maria Mantas
In a prospective cohort of 159,347 US adults, higher adherence to 6 healthy dietary patterns was associated with lower risk of subjective cognitive decline (SCD).
In a prospective cohort of 159,347 US adults, higher adherence to 6 healthy dietary patterns was associated with lower risk of subjective cognitive decline (SCD).
In a prospective cohort of...
03/02/2026
Neurology
a colorful illustration of the brain
News
Five-Year Ublituximab Efficacy Sustained in Relapsing MS Trial
02/23/2026
Maria Mantas
Ublituximab provided sustained reductions in disease activity and disability progression over 5 years in adults with relapsing multiple sclerosis (RMS), according to open-label extension study findings.
Ublituximab provided sustained reductions in disease activity and disability progression over 5 years in adults with relapsing multiple sclerosis (RMS), according to open-label extension study findings.
Ublituximab provided sustained...
02/23/2026
Neurology
a row of pill bottles on a shelf
News
Cenobamate Shows Superior Effectiveness in Drug-Resistant Focal Epilepsy
02/17/2026
Maria Mantas
A large, pooled analysis found that cenobamate outperformed brivaracetam, lacosamide, and perampanel as adjunctive therapy in adults with drug-resistant focal epilepsy.
A large, pooled analysis found that cenobamate outperformed brivaracetam, lacosamide, and perampanel as adjunctive therapy in adults with drug-resistant focal epilepsy.
A large, pooled analysis found...
02/17/2026
Neurology
Two doctors review research data on a computer in a lab
News
Intravenous Tenecteplase Improves Functional Outcomes in Extended-Window Non-LVO Stroke
02/12/2026
Brionna Mendoza
The OPTION randomized clinical trial investigated whether intravenous tenecteplase administered in an extended time window after ischemic stroke onset benefits patients with non-large vessel occlusion (non-LVO) and evidence of salvageable...
The OPTION randomized clinical trial investigated whether intravenous tenecteplase administered in an extended time window after ischemic stroke onset benefits patients with non-large vessel occlusion (non-LVO) and evidence of salvageable...
The OPTION randomized clinical...
02/12/2026
Neurology
a doctor reviews brain scans
News
Phase 2 Odatroltide Trials Show Promise for Acute Ischemic Stroke Patients
02/09/2026
Maria Mantas
Data from 2 phase 2 trials suggest that LT3001 (odatroltide), a novel dual-mechanism stroke therapy, may offer functional improvement in patients with acute ischemic stroke who cannot receive standard reperfusion treatments.
Data from 2 phase 2 trials suggest that LT3001 (odatroltide), a novel dual-mechanism stroke therapy, may offer functional improvement in patients with acute ischemic stroke who cannot receive standard reperfusion treatments.
Data from 2 phase 2 trials...
02/09/2026
Neurology
An orange prescription container with generic pills spilling out in front of it
News
Antidepressant Use Not Linked to Worse Traumatic Brain Injury Outcomes
02/03/2026
Brionna Mendoza
A large nationwide cohort study found no evidence that preinjury antidepressant use increases short-term mortality, need for emergency brain surgery, or length of hospitalization following TBI.
A large nationwide cohort study found no evidence that preinjury antidepressant use increases short-term mortality, need for emergency brain surgery, or length of hospitalization following TBI.
A large nationwide cohort study...
02/03/2026
Psych Congress Network
a mother and daughter sit at a table
News
Fremanezumab Reduces Migraine Days in Pediatric Episodic Migraine
01/30/2026
Maria Mantas
In a recent randomized, placebo-controlled trial, researchers found that fremanezumab significantly reduced monthly migraine days compared with placebo in children and adolescents with episodic migraine. 
In a recent randomized, placebo-controlled trial, researchers found that fremanezumab significantly reduced monthly migraine days compared with placebo in children and adolescents with episodic migraine. 
In a recent randomized,...
01/30/2026
Neurology
fda building sign
News
FDA Approves Copper Histidinate Treatment for Pediatric Menkes Disease
01/19/2026
Brionna Mendoza
The US Food and Drug Administration (FDA) approved a copper histidinate (Zycubo) injection as the first treatment for Menkes disease in pediatric patients.
The US Food and Drug Administration (FDA) approved a copper histidinate (Zycubo) injection as the first treatment for Menkes disease in pediatric patients.
The US Food and Drug...
01/19/2026
Neurology
brain scans
News
Endovascular Thrombectomy Shows Durable 3-Year Benefit in Basilar Artery Occlusion
01/06/2026
Maria Mantas
Endovascular thrombectomy (EVT) provides durable functional and survival benefits for patients with acute basilar artery occlusion, according to long-term follow-up data from a randomized clinical trial. 
Endovascular thrombectomy (EVT) provides durable functional and survival benefits for patients with acute basilar artery occlusion, according to long-term follow-up data from a randomized clinical trial. 
Endovascular thrombectomy (EVT)...
01/06/2026
Neurology

Migraine CME Series

News

A nurse and a doctor review information on a computer in a lab clinical study research trial
News
Fenebrutinib for Multiple Sclerosis Returns Significant Phase III Results
03/04/2026
Brionna Mendoza
The pivotal Phase III FENhance 1 trial of fenebrutinib met its primary endpoint in relapsing multiple sclerosis (RMS), demonstrating statistically significant and clinically meaningful reductions in relapse activity.
The pivotal Phase III FENhance 1 trial of fenebrutinib met its primary endpoint in relapsing multiple sclerosis (RMS), demonstrating statistically significant and clinically meaningful reductions in relapse activity.
The pivotal Phase III FENhance 1...
03/04/2026
Neurology
a bowl of fruits and vegetables indicates brain health
News
DASH Diet Linked to Lower Subjective Cognitive Decline Risk
03/02/2026
Maria Mantas
In a prospective cohort of 159,347 US adults, higher adherence to 6 healthy dietary patterns was associated with lower risk of subjective cognitive decline (SCD).
In a prospective cohort of 159,347 US adults, higher adherence to 6 healthy dietary patterns was associated with lower risk of subjective cognitive decline (SCD).
In a prospective cohort of...
03/02/2026
Neurology
a colorful illustration of the brain
News
Five-Year Ublituximab Efficacy Sustained in Relapsing MS Trial
02/23/2026
Maria Mantas
Ublituximab provided sustained reductions in disease activity and disability progression over 5 years in adults with relapsing multiple sclerosis (RMS), according to open-label extension study findings.
Ublituximab provided sustained reductions in disease activity and disability progression over 5 years in adults with relapsing multiple sclerosis (RMS), according to open-label extension study findings.
Ublituximab provided sustained...
02/23/2026
Neurology
a row of pill bottles on a shelf
News
Cenobamate Shows Superior Effectiveness in Drug-Resistant Focal Epilepsy
02/17/2026
Maria Mantas
A large, pooled analysis found that cenobamate outperformed brivaracetam, lacosamide, and perampanel as adjunctive therapy in adults with drug-resistant focal epilepsy.
A large, pooled analysis found that cenobamate outperformed brivaracetam, lacosamide, and perampanel as adjunctive therapy in adults with drug-resistant focal epilepsy.
A large, pooled analysis found...
02/17/2026
Neurology
Two doctors review research data on a computer in a lab
News
Intravenous Tenecteplase Improves Functional Outcomes in Extended-Window Non-LVO Stroke
02/12/2026
Brionna Mendoza
The OPTION randomized clinical trial investigated whether intravenous tenecteplase administered in an extended time window after ischemic stroke onset benefits patients with non-large vessel occlusion (non-LVO) and evidence of salvageable...
The OPTION randomized clinical trial investigated whether intravenous tenecteplase administered in an extended time window after ischemic stroke onset benefits patients with non-large vessel occlusion (non-LVO) and evidence of salvageable...
The OPTION randomized clinical...
02/12/2026
Neurology
a doctor reviews brain scans
News
Phase 2 Odatroltide Trials Show Promise for Acute Ischemic Stroke Patients
02/09/2026
Maria Mantas
Data from 2 phase 2 trials suggest that LT3001 (odatroltide), a novel dual-mechanism stroke therapy, may offer functional improvement in patients with acute ischemic stroke who cannot receive standard reperfusion treatments.
Data from 2 phase 2 trials suggest that LT3001 (odatroltide), a novel dual-mechanism stroke therapy, may offer functional improvement in patients with acute ischemic stroke who cannot receive standard reperfusion treatments.
Data from 2 phase 2 trials...
02/09/2026
Neurology
An orange prescription container with generic pills spilling out in front of it
News
Antidepressant Use Not Linked to Worse Traumatic Brain Injury Outcomes
02/03/2026
Brionna Mendoza
A large nationwide cohort study found no evidence that preinjury antidepressant use increases short-term mortality, need for emergency brain surgery, or length of hospitalization following TBI.
A large nationwide cohort study found no evidence that preinjury antidepressant use increases short-term mortality, need for emergency brain surgery, or length of hospitalization following TBI.
A large nationwide cohort study...
02/03/2026
Psych Congress Network
a mother and daughter sit at a table
News
Fremanezumab Reduces Migraine Days in Pediatric Episodic Migraine
01/30/2026
Maria Mantas
In a recent randomized, placebo-controlled trial, researchers found that fremanezumab significantly reduced monthly migraine days compared with placebo in children and adolescents with episodic migraine. 
In a recent randomized, placebo-controlled trial, researchers found that fremanezumab significantly reduced monthly migraine days compared with placebo in children and adolescents with episodic migraine. 
In a recent randomized,...
01/30/2026
Neurology
fda building sign
News
FDA Approves Copper Histidinate Treatment for Pediatric Menkes Disease
01/19/2026
Brionna Mendoza
The US Food and Drug Administration (FDA) approved a copper histidinate (Zycubo) injection as the first treatment for Menkes disease in pediatric patients.
The US Food and Drug Administration (FDA) approved a copper histidinate (Zycubo) injection as the first treatment for Menkes disease in pediatric patients.
The US Food and Drug...
01/19/2026
Neurology
brain scans
News
Endovascular Thrombectomy Shows Durable 3-Year Benefit in Basilar Artery Occlusion
01/06/2026
Maria Mantas
Endovascular thrombectomy (EVT) provides durable functional and survival benefits for patients with acute basilar artery occlusion, according to long-term follow-up data from a randomized clinical trial. 
Endovascular thrombectomy (EVT) provides durable functional and survival benefits for patients with acute basilar artery occlusion, according to long-term follow-up data from a randomized clinical trial. 
Endovascular thrombectomy (EVT)...
01/06/2026
Neurology

Alzheimer's Disease CME Series

Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/17/2020
Neurology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use